The consequences of US tariffs on Mexican imports of medtech would be almost imponderable, given Mexico’s world-leading role as the medtech nearshoring gateway to the US. Some 90% of its global exports – worth US$11.3bn in 2021 – go to the US. That figure is twice the size of Mexico’s domestic market.
Mexico’s Medtech Ecosystem Weighs US Tariff Moves But Braces For Turmoil
‘Great Uncertainty’ For Manufacturing, Bilateral Trade And ‘Unprecedented Economic Implications’
The US administration added another layer of confusion after its overnight pronouncements on Mexican tariffs. For medtech, the uncertainty remains, and while the potential impact on the industry might still seem to be a simple question of bilateral trade math, which in itself is huge, the ramifications go even deeper – and wider, writes Bernard Murphy.
More from North America
• By
Mass FDA layoffs on 1 April were designed to spare product reviewers, but still touched many who are critical to the application review process or drug development, which could mean fewer treatments are brought to the US market first.
• By
About 200 staff in the FDA’s Center for Devices and Radiological Health were among the 3,500 FDA employees let go in today’s staff reductions. The cuts, which one employee described as a “Manhattan Project” to the center, are already having a major effect on staff morale.
AdvaMed’s top priorities for the 119th Congress include modernizing US Medicare services and expanding patients’ access to the latest medical technologies.
• By
Abbott presented late-breaking data at the 2025 American College of Cardiology conference demonstrating that TriClip transcatheter edge-to-edge repair offers prolonged patient benefits compared to medical treatment alone after two years, which were not evident at one year.
More from Policy & Regulation
• By
The Visby Medical Women’s Sexual Health Test is the first over-the-counter test cleared by the US Food and Drug Administration to detect chlamydia, gonorrhea and trichomoniasis. It delivers results in about 30 minutes.
• By
A federal judge in Texas delivered what is most likely a fatal blow to the US FDA’s final rule, which would have regulated lab-developed tests as medical devices.
• By
Cybersecurity, sustainability and regulatory intelligence all need factoring into risk management today as AI and data availability change the goalposts. Eight experts tell Medtech Insight how compliance efforts must adapt.